YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China
Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced today that its high‑concentration antibody formulation for...
YZY Biopharma
Wuhan YZY Biopharma Announces Interim Phase II Results for M701 in Malignant Pleural Effusion
Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) today disclosed interim data from its Phase II clinical...
Wuhan YZY Biopharma’s M701 Shows Promise in Phase II Study for Malignant Pleural Effusion at ESMO ASIA 2024
China-based Wuhan YZY Biopharma Co., Ltd (HKG: 2496) has announced the presentation of results from...
Wuhan YZY Biopharma Grants Rights to CD3/EpCAM Antibody M701 to Chi Ta TianQing Pharma in China
Wuhan YZY Biopharma Co., Ltd (HKG: 2496) has announced that it has granted Chi Ta...
Wuhan YZY Biopharma Presents M701 Interim Results at 2024 ESMO Congress for NSCLC-Related Pleural Effusion
Wuhan YZY Biopharma Co., Ltd (HKG: 2496), a biopharmaceutical company based in China, has announced...
Chinese Biopharma Companies Set to Showcase Oncology Pipelines at ASCO 2024
A cohort of Chinese biopharmaceutical companies, including Wuhan YZY Biopharma Co., Ltd (HKG: 2496), Suzhou...
Wuhan YZY Biopharma Initiates Phase II Study for M701 in Malignant Pleural Effusion Treatment
Wuhan YZY Biopharma Co., Ltd (HKG: 2496), a biopharmaceutical company based in China, has announced...
Wuhan YZY Biopharma Aims to Raise HKD 220 Million in Hong Kong IPO
Wuhan YZY Biopharma Co., Ltd, (HKG: 2496) a biopharmaceutical company specializing in targeted cancer drugs...
Wuhan YZY Biopharma Files for IPO on Hong Kong Stock Exchange
China-based Wuhan YZY Biopharma Co., Ltd, a biopharmaceutical company focused on targeted cancer drugs and...
CMS Acquires Wuhan YZY Biopharma’s Bispecific Antibody Assets for Fundus Disease
China Medical System Holdings (CMS; HKG: 0867) announced an asset transfer agreement with Wuhan YZY...
Chongqing Lummy Pharma Cancels YZY Biopharma Y400 Partnership, Secures Compensation
China’s Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) announced the termination of its strategic partnership...
Wuhan YZY Biopharma Raises RMB 200M for Bispecific Antibodies and COVID-19 Vaccine Development
China-based Wuhan YZY Biopharma Co., Ltd has reportedly raised RMB 200 million (USD 29.8 million)...